Next Article in Journal
The Preventive Effect of Dietary Antioxidants against Cervical Cancer versus the Promotive Effect of Tobacco Smoking
Next Article in Special Issue
Effects of Sleep Deprivation on Blood Glucose, Food Cravings, and Affect in a Non-Diabetic: An N-of-1 Randomized Pilot Study
Previous Article in Journal
Rural Resident Experience on National Basic Public Health Services: A Cross-Sectional Survey in 10 Western Provinces of China
Previous Article in Special Issue
Randomized Single-Case Experimental Designs in Healthcare Research: What, Why, and How?
Open AccessArticle

The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study

1
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2006, Australia
2
Kolling Institute of Medical Research, Royal North Shore Hospital and Northern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW 2064, Australia
3
Charles Perkins Centre, University of Sydney, Camperdown, NSW 2006, Australia
*
Author to whom correspondence should be addressed.
Healthcare 2019, 7(4), 161; https://doi.org/10.3390/healthcare7040161
Received: 6 September 2019 / Revised: 5 November 2019 / Accepted: 9 December 2019 / Published: 12 December 2019
(This article belongs to the Special Issue N-of-1 Trials in Healthcare)
N-of-1 trials may provide insights into the impact of deprescribing medications in populations where evidence is currently lacking, such as the effect of statins on cognition in people with dementia. For this pilot, N-of-1, double-blinded, deprescribing trial, adults over 80 years of age with dementia taking statins for at least 6-months were recruited from a hospital’s geriatric medicine outpatient clinic in Sydney, Australia. Participants discontinued and restarted statins over the study period. At enrolment, the hospital pharmacy—using a random number generator, randomised recruited participants to their usual statin or placebo regimen, with assessment and switching of treatment every 5 weeks from baseline (0-weeks) until Visit 4 (15-weeks). Primary outcome was measured using the rate of change in Alzheimer’s Disease Assessment Score-Cognitive Subscale (ADAS-CoG). Over 6-months, 81 participants were screened, 14 were eligible, and four were randomised. One participant (female, 88 years) completed all four assessments with no major harms reported. Cognitive impairment, as measured by ADAS-CoG score, was similar on placebo (15.5/70) compared to statin (15/70). This study suggests there are significant challenges in performing N-of-1 trials and recruiting people with dementia into deprescribing trials from outpatient settings. View Full-Text
Keywords: N-of-1 trials; deprescribing; dementia; statins; feasibility study N-of-1 trials; deprescribing; dementia; statins; feasibility study
Show Figures

Figure 1

MDPI and ACS Style

Clough, A.J.; Hilmer, S.N.; Naismith, S.L.; Gnjidic, D. The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study. Healthcare 2019, 7, 161. https://doi.org/10.3390/healthcare7040161

AMA Style

Clough AJ, Hilmer SN, Naismith SL, Gnjidic D. The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study. Healthcare. 2019; 7(4):161. https://doi.org/10.3390/healthcare7040161

Chicago/Turabian Style

Clough, Alexander J.; Hilmer, Sarah N.; Naismith, Sharon L.; Gnjidic, Danijela. 2019. "The Feasibility of Using N-Of-1 Trials to Investigate Deprescribing in Older Adults with Dementia: A Pilot Study" Healthcare 7, no. 4: 161. https://doi.org/10.3390/healthcare7040161

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop